Open AccessA case report of metastatic lung adenocarcinoma with long-term survival for over 11 years
Author(s) -
Tatsu Matsuzaki,
Eri Iwami,
Kotaro Sasahara,
Aoi Kuroda,
Takahiro Nakajima,
Takeshi Terashima
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000014100
Subject(s) - medicine , carboplatin , erlotinib , pleural effusion , docetaxel , lung cancer , adenocarcinoma , malignant pleural effusion , osimertinib , chemotherapy , oncology , epidermal growth factor receptor , pemetrexed , cancer , surgery , cisplatin
Rationale: This is the first known report in the English literature to describe a case of metastatic non-small cell lung cancer that has been controlled for >11 years. Patient concerns: A 71-year-old man visited our hospital because of dry cough. Diagnosis: Chest computed tomography revealed a tumor on the left lower lobe with pleural effusion, and thoracic puncture cytology indicated lung adenocarcinoma. Interventions: Four cycles of carboplatin and docetaxel chemotherapy reduced the size of the tumor; however, it increased in size after 8 months, and re-challenge chemotherapy (RC) with the same drugs was performed. Repeated RC controlled disease activity for 6 years. After the patient failed to respond to RC, erlotinib was administered for 3 years while repeating a treatment holiday to reduce side effects. The disease progressed, and epidermal growth factor receptor ( EGFR ) gene mutation analysis of cells from the pleural effusion detected the T790 M mutation. Therefore, osimertinib was administered, which has been effective for >1 year. Outcomes: The patient has survived for >11 years since the diagnosis of lung cancer. Lessons: Long-term survival may be implemented by actively repeating cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitor administration.